These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21079400)

  • 1. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
    Załeska M; Szturmowicz M; Zych J; Roszkowska-Sliz B; Demkow U; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
    Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
    Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
    Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
    Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
    Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic markers for stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N
    Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
    Nieder C; Andratschke N; Jeremic B; Molls M
    Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of tumor markers in monitoring of cytotoxic treatment of non-small cell lung cancer].
    Załeska M
    Pneumonol Alergol Pol; 2003; 71(7-8):359-64. PubMed ID: 15052970
    [No Abstract]   [Full Text] [Related]  

  • 16. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung].
    De Angelis G; De Marinis F; Bigioni D; Migliorino MR; Alma MG; Pigorini F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445
    [No Abstract]   [Full Text] [Related]  

  • 17. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
    Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
    Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
    Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
    Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.